Show simple item record

dc.contributor.authorVillar-López, Martha
dc.contributor.authorSoto-Becerra, Percy
dc.contributor.authorCurse Choque, Ruth
dc.contributor.authorAl-kassab-Córdova, Ali
dc.contributor.authorBernuy-Barrera, Félix
dc.contributor.authorPalomino, Henry
dc.contributor.authorRojas, Percy A.
dc.contributor.authorVera, Carmela
dc.contributor.authorLugo-Martínez, Gabriela
dc.contributor.authorMezones-Holguín, Edward
dc.date.accessioned2022-01-05T14:16:30Z
dc.date.available2022-01-05T14:16:30Z
dc.date.issued2021-01-01
dc.identifier.issn09513590
dc.identifier.doi10.1080/09513590.2021.1960965
dc.identifier.urihttp://hdl.handle.net/10757/658457
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es_PE
dc.description.abstractObjective: To evaluate the safety and tolerability of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids (Warmi®, Lima Perú;) in otherwise healthy adult women. Methods: This was a phase-I, randomized parallel three arms, double-blinded, and a placebo-controlled clinical trial. A total of 55 participants aged 18-40 were randomly assigned to one of three groups to receive for three months: (1) an oral herbal supplement of 1650 mg/day; (2) an oral herbal supplement of 3300 mg/day; or (3) an oral placebo 3300 mg/day. The primary endpoints were oral safety and tolerability of the supplement. The secondary endpoint was its effect on vital functions, anthropometrics, and laboratory tests. We used an exploratory approach by covariance analysis (ANCOVA) adjusted for the variables’ baseline value for the secondary outcomes. Results: All women completed three months of follow-up, reporting no side effects. Our exploratory analysis revealed that treatment with the herbal supplement of 1650 mg/day was associated with increased glucose and uric acid levels. In comparison, the herbal supplement 3300 mg/day was associated with reduced breathing rate, increased basal temperature, and systolic blood pressure, both compared to the placebo group. However, despite significant differences, none of these was clinically significant. Conclusion: The oral herbal supplement had a favorable safety and tolerability profile in studied women. There is a need to study its potential as an option to treat menopausal symptoms.es_PE
dc.formatapplication/htmles_PE
dc.language.isoenges_PE
dc.publisherTaylor and Francis Ltd.es_PE
dc.relation.urlhttps://www.tandfonline.com/doi/abs/10.1080/09513590.2021.1960965?journalCode=igye20es_PE
dc.rightsinfo:eu-repo/semantics/embargoedAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Academico - UPCes_PE
dc.subjectadult womenes_PE
dc.subjectcitrus flavonoidses_PE
dc.subjectglucosinolateses_PE
dc.subjectHerbal supplementes_PE
dc.subjectphytosterolses_PE
dc.subjectsafetyes_PE
dc.subjecttolerabilityes_PE
dc.titleSafety and tolerability of a natural supplement containing glucosinolates, phytosterols and citrus flavonoids in adult women: a randomized phase I, placebo-controlled, multi-arm, double-blinded clinical triales_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.eissn14730766
dc.identifier.journalGynecological Endocrinologyes_PE
dc.description.peerreviewRevisión por pareses_PE
dc.identifier.eid2-s2.0-85112188291
dc.identifier.scopusidSCOPUS_ID:85112188291
dc.source.journaltitleGynecological Endocrinology
dc.source.volume37
dc.source.issue10
dc.source.beginpage906
dc.source.endpage913
dc.identifier.isni0000 0001 2196 144X


This item appears in the following Collection(s)

Show simple item record